Get involved and help support our advocacy efforts

Take part in the STRAVINSKY Study

What is the STRAVINSKY study?

The STRAVINSKY study aims to provide doctors, policymakers, and members of the public with up-to-date information on the impact of COVID-19 and booster vaccinations on people who are immune vulnerable. STRAVINSKY stands for ‘Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing’.

What are the aims of STRAVINSKY?

Over the next two years, STRAVINSKY aims to build our understanding of who is most clinically vulnerable to COVID-19 infection and identify individuals or disease groups at highest risk. Using this information, STRAVINSKY will be able to assess the effectiveness of any upcoming booster vaccine programmes or new treatment strategies for these patients as well as respond if significant new COVID-19 variants are detected. It will investigate whether an antibody test result can predict an individual’s risk of severe COVID-19 infection.

Who’s involved?

STRAVINSKY is funded by National Institute for Health and Care Research (NIHR). It brings together researchers from 12 UK universities and hospitals, all with expertise in treating patients with different conditions that affect how their immune systems function. The project is led by researchers from the University of Birmingham, University of Southampton, University of Oxford, and Imperial College London.

Take part

STRAVINSKY is recruiting up to 2,600 patients to take part in this research who either have conditions or take medication that affect the functioning of their immune system. Professor Alex Richter from the University of Birmingham says, “We want to recruit up to 2,600 patients who are clinically vulnerable from all backgrounds to take part in our study. Their participation will be crucial in allowing us to build our understanding of the risk of COVID-19 infection experienced by people with different conditions.”